VistaGen Therapeutics (VTGN) Q2 2025 earnings summary

Executive summary

• Advancing a neuroscience pipeline with multiple clinical-stage intranasal pherine product candidates targeting social anxiety disorder (SAD), major depressive disorder (MDD), and menopausal hot flashes, with additional programs in PMDD, cognitive impairment, and NMDAR-related disorders.

• Statistically significant efficacy and favorable safety observed in lead programs: fasedienol (SAD, phase III), itruvone (MDD, phase 2a), and PH80 (menopausal hot flashes, phase 2a).

• PALISADE-3 and PALISADE-4 phase III trials for fasedienol initiated on schedule, aiming for top-line results in 2025 to support NDA submission.

• Itruvone phase 2b protocol for MDD nearing completion, with self-administration planned for the outpatient study.

• PH80 program progressing through IND-enabling studies for U.S. phase II development in hot flashes and exclusive negotiation agreement for Japan.

Financial highlights

• Research and development expenses rose to $10.2 million for the quarter ended September 30, 2024, up from $3.9 million year-over-year, mainly due to increased clinical activity, headcount, and consulting.

• General administrative expenses increased to $4.2 million from $3.2 million year-over-year, driven by higher headcount and professional fees.

• Net loss attributable to common stockholders was $13 million for the quarter, compared to $6.6 million in the prior year.

• Cash, cash equivalents, and marketable securities totaled $97.6 million as of September 30, 2024, down from $119.2 million at March 31, 2024.

• Net cash used in operating activities was $21.8 million for the six months ended September 30, 2024.

Outlook and guidance

• Top-line results for PALISADE-3 expected mid-2025 and for PALISADE-4 by end of 2025; both studies will be completed regardless of individual outcomes.

• NDA submission for fasedienol targeted for early 2026 if trials are positive.

• PH80 IND submission targeted for the second quarter of 2025 to enable further U.S. phase II development.

• Itruvone phase 2b protocol expected to be finalized by year-end or early January.

• Management expects operating losses and negative cash flows to continue for the foreseeable future as research, development, and contract manufacturing activities progress.